Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$76.13 USD

76.13
2,260,926

+2.01 (2.71%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Incyte (INCY) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 13.79% and 3.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More

by Ahan Chakraborty

Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.

Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline

by Zacks Equity Research

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 87.50% and 36.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study

by Zacks Equity Research

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.

New Strong Sell Stocks for June 16th

by Zacks Equity Research

ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.

Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (INCY) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte

by Zacks Equity Research

Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Fomento Economico Mexicano, NextEra Energy & Charter Communications

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Charter Communications, Inc. (CHTR).

The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio

by Zacks Equity Research

Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.

Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates

by Ekta Bagri

Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Molina Healthcare (MOH) in Q1 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.

Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo

by Zacks Equity Research

Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

by Zacks Equity Research

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks

by Zacks Equity Research

Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

by Zacks Equity Research

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.